Akorn, Inc. (AKRX) was a pharmaceutical company that focused on developing, manufacturing, and marketing generic and branded prescription pharmaceuticals, as well as animal and consumer health products. The company was headquartered in Lake Forest, Illinois, and operated in the United States, India, and Switzerland.
In 2020, the company filed for Chapter 11 bankruptcy and its assets were subsequently acquired by another pharmaceutical company. Prior to its bankruptcy, the company faced several challenges, including regulatory issues with the Food and Drug Administration (FDA) regarding the manufacturing of some of its products.
Akorn's stock was delisted from the NASDAQ exchange in 2020 and is no longer publicly traded.
Akorn, Inc. (AKRX) was a pharmaceutical company that focused on developing, manufacturing, and marketing generic and branded prescription pharmaceuticals, as well as animal and consumer health products. The company was headquartered in Lake Forest, Illinois, and operated in the United States, India, and Switzerland.